Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid.

Donate
Sign Up
Main Menu

Developing Rapid System for Outlier Analysis in ME/CFS

PROTOCOL AIM
Establish an analytical workflow for outlier analysis in ME/CFS to identify disease or symptom exacerbators that may not be considered in the individual with ME/CFS (including gene mutations, elevated toxins) and then develop a software program to rapidly identify these potential anomalies.
LEAD INVESTIGATORS
  • Christopher Armstrong, PhD
  • Paul Gooley, PhD
  • Neil McGregor, PhD
  • David Ascher, PhD
PROTOCOL VALUE

This software would rapidly identify disease or symptom exacerbators that may be due to genetic mutation of environmental stressors in individuals with ME/CFS. This will provide a better understanding of the symptom expression in ME/CFS and help identify secondary issues or chronic triggers that are exacerbating/maintaining the disease.

Identifying these issues or stressors will enable them to be more accurately treated and improve quality of life in people with ME/CFS 

PROTOCOL DESCRIPTION

The software developed would use machine learning to identify outlier anomalies that are consistent across genomics, proteomics, and metabolomics data from an individual. A report would be produced to highlight the probability of genetic mutations relating to a functional effect.

PROTOCOL DEVELOPMENT

The data required to develop this software will be immense and will consist of many previously produced datasets from our collaborators. A significant amount of priming and testing of this software will occur through the accumulation of genomics, metabolomics and symptom data from 300 ME / CFS patients.

Gene mutations, metabolite levels and symptom data will be analyzed to identify outlier metabolites and metabolites that relates strongly to symptom data. Genetic mutations and environmental factors will be considered causes of these outliers by machine-learning technology.

Software will be developed specifically to store patterns developed from patient data and more rapidly check those patterns against new patient data to rapidly identify potential issues that may be exacerbating or triggering symptoms in people with ME / CFS.

Other links you might be interested in:
Four Tips to Make Your Facebook Fundraiser a Success
Melbourne ME/CFS Collaboration
Facebook Twitter Youtube Instagram Linkedin
OMF is a non-profit 501(c)(3) organization
(EIN# 26-4712664). All donations are tax-deductible to the full extent allowed by law.

Open Medicine Foundation®
29302 Laro Drive,  Agoura Hills, CA 91301 USA
Phone: 650-242-8669
info@omf.ngo

Contact Us

PRIVACY  |  COOKIE   |   CONSENT   |  MEDICAL & OTHER DISCLAIMERS

Copyright © 2023 Open Medicine Foundation. All Rights Reserved.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 
 

Consent management

Consent Preferences

Data Subject Access Request (DSAR) Form 

Donate